A Phase 3 interventional study of Actonel® and Denosumab in Osteoporosis, sponsored by Amgen. Completed. Open to female participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2020-07-28.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing denosumab in Osteoporosis — 8 open to participants now, 11 under way, 2 of them phase 3. Denosumab · Osteoporosis.
Among the 64 studies testing denosumab in Osteoporosis, this one is the 5th largest by enrollment, is one of 5 that started in 2009, is one of 24 in phase 3, and was the 14th registered.
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
Browse Osteoporosis studies →8 of the 64 studies testing denosumab in Osteoporosis are open now, in 8 countries. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 50–80 · Women only
Qilu Pharmaceutical Co., Ltd. · Sites in China
Ages 50–85 · Women only
Aarhus University Hospital · Sites in Denmark
Ages 40+ · Women only
Chrissy Kistler · Sites in United States
Ages 65+
Wuhan Union Hospital, China · Sites in China
Ages 40+
By country, each count listing its studies:
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 55 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 16 · Phase 3 25 · Phase 4 19
First in 2002; this study’s year is marked. 5 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 870 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 90 across the 64 interventional studies. Of the 45 that completed or were terminated, 32 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 64 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
34 studies in Osteoporosis by Amgen: none open now, 2 under way, none of them phase 3. Of 32 finished, 31 (97%) have results posted.
Among the 34 studies in Osteoporosis by Amgen, this one is the 6th largest by enrollment of the 32 interventional ones that give a count, is one of 5 that started in 2009, is one of 18 in phase 3, and was the 14th registered.
Amgen’s Osteoporosis studies by the year they started, since 2002.
6 of the studies testing denosumab in Osteoporosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07062978Phase 3Qilu Pharmaceutical Co., Ltd.A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia® | 2027-01 |
| NCT06332014AmgenEvaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China | 2027-01-23 |
| NCT04608630Australian and New Zealand Intensive Care Research CentreBone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults | 2027-02-28 |
| NCT04800367Columbia UniversityRomosozumab/Denosumab Study for Premenopausal IOP | 2027-03 |
| NCT07271771Aarhus University HospitalThe Effect of Denosumab on Muscle and Strength and Insulin Sensitivity | 2027-03-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 64 studies testing denosumab in Osteoporosis, from their registry updates:
Among Amgen’s 34 in Osteoporosis:
This tab as a report to print or save as PDF → With an account.
A randomized, open label study to assess the safety and effectiveness of Denosumab, administered every 6 months and Actonel ® (Risedronate), administered monthly in post menopausal women transitioned from weekly or daily Alendronate therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Denosumab
Drug: Actonel®
Total Hip BMD Percent Change From Baseline at Month 12
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry
Time frame: Baseline to month 12
Serum CTX Percent Change From Baseline at Month 1
Serum Type-1 Collagen C-Telopeptide Percent Change From Baseline at Month 1
Time frame: Baseline to month 1
Femoral Neck BMD Percent Change From Baseline at Month 12
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry
Time frame: Baseline to month 12
Lumbar Spine BMD Percent Change From Baseline at Month 12
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry
Time frame: Baseline to month 12
Participants were enrolled from 19 October 2009 through 4 January 2011
| Milestone | Risedronate 150 mg QM | Denosumab 60 mg Q6M |
|---|---|---|
| Started | 435 | 435 |
| Completed | 402 | 422 |
| Not completed | 33 | 13 |
| Withdrew: Withdrawal by subject | 15 | 7 |
| Withdrew: Adverse event | 13 | 3 |
| Withdrew: Other | 1 | 2 |
| Withdrew: Administrative decision | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Noncompliance | 1 | 0 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry
| Percent Change From Baseline | Risedronate 150 mg QM | Denosumab 60 mg Q6M |
|---|---|---|
| Total Hip BMD Percent Change From Baseline at Month 12 | 0.5 (0.2 to 0.7) | 2.0 (1.8 to 2.3) |
Serum Type-1 Collagen C-Telopeptide Percent Change From Baseline at Month 1
| Percent Change From Baseline | Risedronate 150 mg QM | Denosumab 60 mg Q6M |
|---|---|---|
| Serum CTX Percent Change From Baseline at Month 1 | -17.0 (-36.8 to -1.6) | -77.7 (-85.9 to -67.6) |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry
| Percent Change From Baseline | Risedronate 150 mg QM | Denosumab 60 mg Q6M |
|---|---|---|
| Femoral Neck BMD Percent Change From Baseline at Month 12 | 0.0 (-0.4 to 0.3) | 1.4 (1.0 to 1.7) |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry
| Percent Change From Baseline | Risedronate 150 mg QM | Denosumab 60 mg Q6M |
|---|---|---|
| Lumbar Spine BMD Percent Change From Baseline at Month 12 | 1.1 (0.7 to 1.5) | 3.4 (3.1 to 3.8) |
Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Risedronate 150 mg QM | — | 35/429 (8.2%) | 0/429 (0%) |
| Denosumab 60 mg Q6M | — | 33/429 (7.7%) | 0/429 (0%) |
| Event | Risedronate 150 mg QM | Denosumab 60 mg Q6M |
|---|---|---|
| Atrial fibrillationCardiac disorders | 0/429 | 2/429 |
| Coronary artery stenosisCardiac disorders | 2/429 | 0/429 |
| Radius fractureInjury, poisoning and procedural complications | 0/429 | 2/429 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/429 | 2/429 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/429 | 2/429 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/429 | 1/429 |
| Cerebral ischaemiaNervous system disorders | 0/429 | 2/429 |
| Cerebrovascular accidentNervous system disorders | 0/429 | 2/429 |
| Atrial flutterCardiac disorders | 1/429 | 0/429 |
| Cardiac arrestCardiac disorders | 1/429 | 0/429 |
| Age, Continuous(Years) | Risedronate 150 mg QM | Denosumab 60 mg Q6M | Total |
|---|---|---|---|
| Mean | 67.7 ± 6.8 | 67.8 ± 7.0 | 67.7 ± 6.9 |
| Sex: Female, Male(Participants) | Risedronate 150 mg QM | Denosumab 60 mg Q6M | Total |
|---|---|---|---|
| Female | 435 | 435 | 870 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Risedronate 150 mg QM | Denosumab 60 mg Q6M | Total |
|---|---|---|---|
| White or Caucasian | 425 | 424 | 849 |
| Hispanic or Latino | 6 | 7 | 13 |
| Asian | 4 | 3 | 7 |
| Japanese | 0 | 1 | 1 |
No study locations are listed for this record.
Ran from Sep 2009 to primary completion in Dec 2011, 27 months.
Results were first posted in Dec 2012, 11 months after primary completion.
Of 35 industry-sponsored phase 3 interventional studies under Osteoporosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 46. This study's 27 months is above that.
Counting every sponsor, half of 45 studies reached it within 37 months; a quarter within 21 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab